NON SMALL CELL LUNG CANCER NSCLC

This study tests a vaccine designed to help the immune system recognize and attack non-small cell lung cancer. The vaccine uses a piece of the MUC1 protein, which is often found on cancer cells, mixed with an immune booster called Poly-ICLC. About 30 adults with stable, early or …

This study tests a new drug called Rina-S in about 240 people with advanced non-small cell lung cancer. The goal is to see if Rina-S can shrink tumors or stop them from growing. All participants receive the active drug, and treatment may continue as long as it helps and side effe…

This study is for people with stage III lung cancer whose tumor has come back in the chest after previous treatment with chemotherapy, radiation, and the drug durvalumab. Participants will receive targeted radiation to the tumor, followed by two drugs: durvalumab (an immunotherap…

This study tests whether the drug taletrectinib can prevent non-small cell lung cancer from returning in people whose tumors have been fully removed by surgery. About 180 adults with a specific genetic marker (ROS1-fusion) and stage IB to IIIA cancer will receive either taletrect…

This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors (cancers that have spread). The drug is designed to help the immune system fight cancer. The trial has two parts: first, finding a safe dose, and then seeing if it shrinks tumors. About 7…

This study compares a new drug called pumitamig to the standard treatment pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer whose tumors have high levels of a protein called PD-L1. The goal is to see if pumitamig works better at stopping cancer growth a…

This study tests whether a new drug called pumitamig works better than the current standard drug durvalumab for people with stage III lung cancer that cannot be removed by surgery. Participants must have finished chemotherapy and radiation without their cancer getting worse. The …

This phase 3 study tests whether adding the experimental drug MK-2870 to the standard immunotherapy pembrolizumab helps people with advanced non-small cell lung cancer live longer compared to pembrolizumab alone. About 614 participants whose tumors have high PD-L1 levels will be …

This early-stage study tests a new drug called XL092, alone or with other immune-boosting drugs, in people with advanced solid tumors (like kidney, prostate, lung, or colon cancer) that can't be removed by surgery. The main goals are to find safe doses and see if the treatment sh…

This study tests a new drug called GTAEXS617 in people with advanced solid tumors that have not responded to standard treatments. The goal is to check the drug's safety, how the body processes it, and whether it can shrink tumors. About 230 adults with certain cancers like lung, …

This study is for people with stage IV non-small cell lung cancer whose main tumor and metastases have shrunk after initial chemotherapy, immunotherapy, or targeted therapy. The researchers want to see if also treating the remaining cancer spots with surgery or radiation (called …

This study tests an experimental drug called M9140 in people with advanced solid tumors (stomach, lung, or pancreatic cancer) that have a specific protein (CEACAM5). The drug is designed to deliver a powerful chemotherapy directly to cancer cells. The goal is to see if it can shr…

This early-stage study tests a new drug called STRO-004 in about 200 adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in m…

This study tests a new combination of drugs (RAS(ON) inhibitors plus ivonescimab) in adults with advanced or metastatic solid tumors that have a RAS mutation. The goal is to see if the combination is safe and can shrink tumors or slow their growth. About 370 people with cancers l…

This study tests a new drug, MK-2870, against standard chemotherapy for people with a specific type of advanced lung cancer (EGFR-mutated non-squamous non-small cell lung cancer) that has worsened despite prior targeted therapy. About 520 participants will be randomly assigned to…

This study compares two first-line treatments for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation and no PD-L1 protein. One group gets the targeted pill sotorasib plus chemotherapy; the other gets the immunotherapy pembrolizumab plus chemoth…

This study tests a new drug called STX-241 in people with advanced non-small cell lung cancer that has stopped responding to standard targeted therapies. The drug is designed to reach the brain and attack cancer cells with specific genetic changes. The trial will check safety, fi…

This study tests a new drug (WSD0922-FU) combined with an existing targeted therapy (osimertinib) for people with advanced non-small cell lung cancer that has specific genetic changes (EGFR mutations). The goal is to see if the combination is safe and can shrink tumors or slow th…

This study tests two experimental drugs, elironrasib and daraxonrasib, given alone or together, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drugs are safe and can shrink or control tumors. About 534 adults with lung, col…

This early-stage study tests a new drug called RMC-5127 in adults with advanced solid tumors that have a specific KRAS G12V gene change. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 574 people with lung, colorectal, or panc…

This study tests a new drug called IDE574 in people with advanced solid tumors (like lung, prostate, or colorectal cancer) and a specific type of breast cancer (ER+, HER2-). The drug targets two enzymes that help cancer cells grow. The study will check if IDE574 is safe and can s…

This early-stage study tests a new drug called KO-2806 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the drug can shrink tumors, either alone or combined with other therapies. About 300 adults wi…

This study is testing new drugs called RAS(ON) inhibitors in people with advanced non-small cell lung cancer that has a RAS mutation. The goal is to see if these drugs are safe and can shrink tumors or slow the cancer's growth. About 616 adults will receive the drugs alone or wit…

This early-phase study tests an experimental pill called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The drug aims to boost the body's immune system to fight tumors. The main goals are to check safety and see if the drug can shrink or c…

This study tests an experimental drug called patritumab deruxtecan in people with advanced solid tumors that have spread or cannot be removed. The trial includes 740 participants with 13 different cancer types, such as lung, breast, and prostate cancer. The goal is to see if the …

This study tests an experimental drug called BMS-986523, either alone or with other cancer medicines, in people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have a specific genetic change (KRAS). The main goals are to see if the drug is safe and to fin…

This study tests a new drug, datopotamab deruxtecan, against a standard chemotherapy (docetaxel) in people with advanced or metastatic non-squamous non-small cell lung cancer that has a specific protein called TROP2. The goal is to see if the new drug helps people live longer or …

This study tests a treatment using donor immune cells (CAR-NK cells) designed to attack cancer. The specific target on the cancer cells is chosen based on a biopsy of the tumor or a blood test. The goal is to see if this approach is safe and can shrink or control advanced solid t…

This study tests an experimental drug called MT-4561 in people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have run out of standard options. The goal is to find a safe dose and see if the drug can shrink tumors. About 27 adults will take part in this …

This early-phase study tests a new drug called TH9619 in people with advanced solid tumors, including colorectal, head and neck, lung, and stomach cancers. The main goal is to find a safe dose and check for side effects. About 43 adults who have already tried at least one standar…

This early-stage study tests the drug gilteritinib in about 40 adults with advanced ALK-positive non-small cell lung cancer whose cancer no longer responds to standard ALK inhibitors. Gilteritinib is already approved for a type of leukemia and may also block faulty ALK signals. T…

This study tests a new drug called JYP0015 in adults with advanced solid tumors that have a specific genetic change called RAS mutation. The goal is to see if the drug is safe and can shrink tumors. About 210 people with pancreatic, lung, or colorectal cancer will take part.

This study tests an inhaled form of the drug azacytidine, given alongside standard chemotherapy and immunotherapy, for people with early-stage non-small cell lung cancer that can be removed by surgery. The goal is to find the safest and most effective dose and see if this combina…

This early-phase study tests a new drug called BMS-986463 in people with advanced ovarian, uterine, or lung cancer that has spread or cannot be removed by surgery. The main goals are to check the drug's safety and find the best dose. About 240 participants will receive increasing…

This early-phase study tests a new experimental drug (LB-LR1109) in people with advanced solid tumors like lung, kidney, or skin cancer that no longer respond to standard treatments. The study has two parts: first, the drug is given alone to find the safest dose; second, it is co…

This study tracks side effects, especially lung-related ones, in 500 Japanese adults with a specific type of non-small cell lung cancer. Participants take Brigatinib tablets as part of their normal care, and doctors record any health issues for one year. The goal is to better und…

This study tests an experimental drug called RMC-6236 in about 754 adults with advanced solid tumors that have specific RAS gene mutations, including certain lung, colorectal, and pancreatic cancers. The main goals are to check the drug's safety and find the right dose. Participa…

This early-stage study is testing a new drug, IDE892, both alone and in combination with another drug called IDE397. It is for adults with advanced solid tumors that have a specific genetic change called MTAP deletion and have stopped responding to standard treatments. The main g…

This study tests a special dye called LS301-IT that makes lung cancer cells glow during surgery. About 35 adults with early-stage lung cancer will receive the dye before their operation. The goal is to see if the dye helps surgeons find tumors that are hard to see with the naked …

This study looks at whether genetic material from lung cancer cells can be collected from a lung wash (bronchoalveolar lavage) instead of a traditional needle biopsy. Researchers will compare the genetic test results from the wash fluid to those from standard biopsy samples in 10…

This study tests whether using an incentive spirometer—a device that encourages deep breathing—can lower the risk of lung inflammation (pneumonitis) in people with advanced lung cancer receiving chemotherapy and radiation. About 100 participants will use the device 10 times every…

This study interviews 55 people — patients with early-stage non-small cell lung cancer and their doctors — to learn what they value most in treatment options. It does not test a new drug or procedure, but aims to gather insights to improve future care decisions. Participants are …

This study is watching how lung cancer patients do when they get a drug called Tislelizumab in regular doctor visits, not in a strict research setting. About 240 people in Germany and Austria will take part. The goal is to see how long they live, how well the treatment works, and…

This early-phase study is testing a new substance called RAD301 in 9 healthy volunteers and people with certain cancers (pancreatic, lung, esophageal, cervical, endometrial, or ovarian). The goal is to see how the body absorbs and handles the radiation from RAD301, and whether it…